What Virion Therapeutics does

Virion Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Philadelphia, Pennsylvania, developing T cell-based immunotherapies for chronic viral infections and cancer. The company's scientific foundation rests on a proprietary platform combining glycoprotein D (gD) checkpoint modifiers with selected disease antigens delivered via ChiVax™ heterologous chimpanzee adenoviral vectors (serotype AdC6 and others). This architecture is designed to lower the CD8+ T cell activation threshold, mitigate T cell exhaustion, and elicit sustained immune responses against sub-dominant epitopes not normally activated by natural infection. Virion's lead clinical candidate, VRON-0200, targets chronic hepatitis B virus (HBV) infection and has completed Phase 1b trials showing durable anti-HBV activity in 92% of patients with continued HBsAg declines up to 2+ years following a single dose — the first such result for a new HBV immune modulator since pegylated interferon. Results were published in The Lancet Microbe in 2026.

Virion's second clinical-stage program, VRON-0300, applies the same checkpoint modifier platform to advanced solid tumors, expanding the pipeline beyond infectious disease. The company addresses a global HBV patient population of approximately 254 million (WHO 2022), with current standard-of-care antivirals rarely achieving functional cure and requiring lifelong therapy. Virion's business model is pre-revenue and clinical-stage: future economics will derive from product sales following regulatory approval, supplemented by partnership, licensing, or potential acquisition by larger pharmaceutical companies. The company operates with 11-50 employees, secured a strategic partnership with Center for Breakthrough Medicines for GMP manufacturing in 2022, and formed a joint venture with publicly-traded Ocean Biomedical (NASDAQ: OCEA) in October 2023 to fund and execute the multinational first-in-humans chronic HBV study. Total disclosed funding to date is approximately $14.2 million across multiple angel/club rounds. The company is event-driven in its go-to-market, leveraging scientific conference presentations (EASL, AASLD, APASL, CROI) and peer-reviewed publications to build clinical awareness among hepatology key opinion leaders.

Name

Virion Therapeutics

Legal name

Virion Therapeutics, LLC

Website

https://viriontx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Virion Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies using proprietary glycoprotein D checkpoint modifiers delivered via ChiVax™ chimpanzee adenoviral vectors, targeting chronic hepatitis B (VRON-0200) and advanced solid tumors (VRON-0300).

Ownership category

akta.pro rank

Product category

Clinical-stage immunotherapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

akta.pro secondary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• T cell immunotherapies
• Checkpoint modifier technology
• Chronic hepatitis B treatment
• Viral vector vaccines
• Oncology biologics

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharmaceutical Development: As a clinical-stage biopharmaceutical company, Virion Therapeutics is pre-revenue. The company is developing VRON-0200 for chronic HBV infection and VRON-0300 for advanced solid tumors. Future revenue is expected from product sales following regulatory approval, with potential for partnership, licensing, or acquisition by larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Virion Therapeutics is a clinical-stage biopharmaceutical company developing T cell-based immunotherapies that combine proprietary checkpoint modifiers (glycoprotein D) with disease-specific antigens delivered via its ChiVax heterologous chimpanzee adenoviral vector platform. Its lead candidate VRON-0200 targets chronic hepatitis B infection with the goal of achieving a functional cure, while VRON-0300 is in development for advanced solid tumors. Both programs are designed to restore, enhance, and sustain CD8+ T cell immune responses.

Product overview

Virion Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of T cell-based immunotherapies utilizing proprietary checkpoint modifiers. The company's core product is VRON-0200 for chronic HBV infection (Phase 1b completed), with VRON-0300 in development for advanced solid tumors. Both programs leverage the ChiVax™ heterologous chimpanzee adenoviral vector platform to restore, enhance, and elicit sustained CD8+ T cell responses. The technology combines genetically encoded checkpoint modifiers (glycoprotein D) with selected disease-specific antigens to address unmet needs in chronic infectious diseases and cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• VRON-0200 First-in-class T cell-based immunotherapy for chronic hepatitis B virus (HBV) infection that combines a genetically encoded checkpoint modifier (glycoprotein D) with selected HBV core and pol antigens, delivered via ChiVax heterologous chimpanzee adenoviral vectors; designed to provide a functional cure by stimulating new CD8+ T cells to restore immune control.
• VRON-0300 Advanced solid tumor program utilizing Virion's proprietary T cell-based immunotherapy platform with checkpoint modifiers for cancer treatment.
• ChiVax Technology Platform

Quantifiable outcome

• 92% of patients with extended follow-up showed continued HBsAg declines up to 2+ years after single VRON-0200 dose
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and important.

• Ocean BiomedicalcoreStrategic or Co-development Partner · 26 October 2023Joint venture partnership for VRON-0200 chronic HBV clinical trial. First patients dosed in October 2023 in the chronic hepatitis B study as part of the joint venture arrangement with Ocean Biomedical.
• Ocean Biomedical (NASDAQ: OCEA)coreStrategic or Co-development Partner · 12 October 2023Virion Therapeutics and Ocean Biomedical formed a joint venture supporting multinational first-in-humans clinical chronic hepatitis B study. The joint venture aims to achieve a functional cure for a disease affecting 300+ million patients worldwide. Ocean Biomedical is a publicly traded company (NASDAQ: OCEA) providing strategic support and resources for the VRON-0200 clinical development program.
• The Wistar InstituteimportantTechnology or Integration · 31 March 2022Dr. Hildegund Ertl, Scientific Founder of Virion Therapeutics, is a Professor in the Vaccine & Immunotherapy Center at The Wistar Institute. The Wistar Institute provides scientific foundation and expertise for Virion's T cell immunotherapy platform.
• Center for Breakthrough MedicinesimportantImplementation/ SI/ Consulting Partner · 22 February 2022Strategic partnership to manufacture Virion's proprietary CD8+ T cell-based clinical development programs for infectious diseases and cancers. Center for Breakthrough Medicines provides GMP manufacturing capabilities for clinical supply.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Arbutus Biopharma: Clinical-stage biopharmaceutical company developing a portfolio of HBV therapeutics including RNAi agents and oral capsid inhibitors aimed at functional cure — directly competing with Virion's VRON-0200 in the HBV functional cure space.
• Assembly Biosciences: Clinical-stage HBV-focused company developing core protein inhibitors and other small-molecule and biologic approaches to functional cure — competing head-to-head with Virion in the chronic hepatitis B market.
• Altimmune: Clinical-stage biopharmaceutical company developing HepTcell, an immunotherapeutic for chronic HBV that aims to stimulate T cell responses — closely comparable therapeutic modality to Virion's VRON-0200.
• Vir Biotechnology: Clinical-stage immunology company developing antibody-based immunotherapies for serious infectious diseases including HBV, with broader pipeline in influenza and HIV — comparable viral-infection immunotherapy focus and clinical stage.
• Brii Biosciences: Clinical-stage biopharmaceutical company with a leading HBV functional cure pipeline (including siRNA and therapeutic vaccine programs) partnered with Brii and major Chinese and global pharma — directly competing in HBV cure development.
• Bluejay Therapeutics: Clinical-stage biotechnology company developing monoclonal antibody and small interfering RNA therapies for chronic HBV — competing in the same HBV functional cure space as Virion.
• Vaccitech: Clinical-stage immunotherapeutic company using viral vector platforms (including chimpanzee adenoviral vectors such as ChAdOx1) to develop T cell–inducing vaccines for infectious diseases and cancer — closely comparable platform technology and therapeutic strategy to Virion's ChiVax.

Broad incumbents

• Gilead Sciences: Large established biopharmaceutical company with leading chronic HBV antiviral franchise (Vemlidy) and active internal HBV cure programs — broad incumbent competing across multiple HBV modalities and a likely strategic acquirer or partner.
• GSK: Global biopharmaceutical company with established HBV vaccine (Engerix/Fendrix) and active HBV cure pipeline assets — broad incumbent operating across infectious disease immunotherapy and a likely partner or acquirer for clinical-stage assets.

Emerging players

• Replimune: Clinical-stage oncology company developing tumor-directed oncolytic immunotherapies — relevant peer for Virion's VRON-0300 solid tumor program given shared strategy of using viral vectors to elicit anti-tumor T cell responses.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/virion-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds12 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virion Therapeutics